[Controversies in the treatment of acute myocardial infarction].
The primary angioplasty in the acute infarction is a documented and applied therapy in nearly 80% of the acute infarction in Switzerland. The usual pharmacological approach can be associated to a thrombo-aspiration at the beginning of the procedure, with a probable benefit on the final coronary flow and a reduction in the risk of "no reflow" (TAPAS study). The selection of a bare metal stent is a consensus established for one decade. The recent meta-analyses of Pasceri and Kastrati have shown at one year, a rate of stent thrombosis, similar among patients treated by a bare metal stent or a drug eluting stent, but with a net benefit on the risk of reintervention for restenosis at mid-term when an eluting stent is implanted.